ABSTRACT
Systematic Reviews and Meta-Analyses Protocols (PRISMA-P). 4. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) will be used to evaluate the quality of evidence.
5. This meta-analysis will be limited to studies which are published in English language and have been peer reviewed.
INTRODUCTION
Injecting drug users are known to be at higher risk of HIV infection than the general population. Data from the United Nations Office on Drugs and Crime (UNODC) indicate that the number of people who inject drugs worldwide is approximately 12.7 million. 1 The 2012 UNODC/WHO/The Joint United Nations Programme on HIV/AIDS (UNAIDS)/World Bank global estimate of the number of people who inject drugs and are living with HIV was 1.7 million (range: 0.9-4.8 million), corresponding to an average prevalence of HIV among people who inject drugs of 13.1%. People who inject opiates, cocaine, cannabis, and amphetamines (including 'ecstasy'). People who primarily misuse alcohol will be excluded from our study.
Interventions
We will include studies with interventions which are defined by WHO, UNODC, and UNAIDS, including: 1 needle and syringe programmes (NSPs); opioid substitution therapy (OST) and other evidence-based drug dependence treatment programmes; HIV testing and counselling (HTC); antiretroviral therapy (ART); prevention and treatment of sexually transmitted infections; condom programmes; targeted information, education, and communication (IEC) for people who inject drugs.
Comparators
Placebo-controlled or no intervention. Studies which compare two different interventions within the same investigation will also be accepted.
Outcomes
We will only accept a study if it contains at least one outcome measure of injection risk behaviour, sexual risk behaviour, or HIV seroconversion.
Study designs and publication types
We will only include randomised controlled trials and publications which have been peer-reviewed.
Language and time frame
We only intend to include studies which are published in English. We will not place any time restriction on the publication year. The search will be performed in May 2018.
Information sources and search strategy
We will search the following databases: Medline, Embase, PsycINFO, and the Cochrane Central Register of Controlled Trials. The search strategy shown below was adapted from a previous review, 13 and improved by conferring with experts in a related field. The search strategies for other databases will be adjusted according to their specific requirements. We will also carry out manual searches of the reference lists of other review articles on related subjects, to retrieve additional studies not identified by our original search. The following search terms will be used: 1. "drug users" OR "drug use" OR "drug abuse" OR "drug abuser" OR "drug abusers OR "drug addict*" OR "substance abuse" OR "substance dependence" OR "drug dependence" OR "drug dependency" OR "IDU" OR "IDUs" OR "injecting drug" OR "intravenous drug" OR "intravenous substance" OR "injecting substance" OR exp F o r p e e r r e v i e w o n l y substance abuse, intravenous/ 2. "HIV" OR "AIDS" OR "acquired immunodeficiency syndrome" OR "Acquired Immunodeficiency Syndrome Virus" OR "AIDS Virus" OR "AIDS Viruses" OR "Immunologic Deficiency Syndrome, Acquired" OR "Acquired Immune Deficiency Syndrome" OR exp HIV/ OR exp HIV Infections/ 3. #1 AND #2 4. *Randomised Controlled Trial/OR (Randomised Controlled Trial).pt OR *Random Allocation/. 5. (Randomised OR randomised OR (random* adj (assigned OR allocated OR assignment OR allocation))). ab,ti. 6. #4 OR #5 7. #3 AND #6
Study selection
We will import the search results into EndNote (data management software). After removing duplicate articles, the first two authors will independently read the titles and abstracts to select eligible articles according to the inclusion criteria. Then we will obtain the full-texts of all articles which appear to meet the inclusion criteria or where there is any uncertainty. The first two authors will conduct full-text reviews alone to confirm the eligibility of these articles. Cohen's Kappa (κ) will be used to measure the chance-corrected agreement between the two authors. Any discrepancies will be resolved by discussion with a third author and the reasons for excluding articles will be recorded.
Data collection process
The first two authors will independently abstract the following information from the articles collected as described above:
1. Study characteristics (first author, journal, year, country, sample size, etc.) 2. Participant characteristics (age, sex, manner of drug use, type of drug, the incidence rate of injection risk behaviours or sexual risk behaviours at baseline, etc.) 3. Intervention characteristics (type, treatment dose, and duration, etc.) 4. Control characteristics 5. Any disagreements will be resolved by discussion with the third author and we will contact the original authors of studies to resolve any uncertainties if necessary.
Outcome measures
Our primary outcome measures will be injection risk behaviours and HIV risk behaviours. We will review all the acquired full-texts to check the relative scale used by each study, then select the authoritative scale, for example the HIV Risk-Taking Behaviour Scale, 14, 15 to assess the above indicators. HIV seroconversion confirmed by an antibody test will be the secondary outcome, if available.
Risk of bias in individual studies
F o r p e e r r e v i e w o n l y
We will use the Cochrane revised tool, Risk of Bias (RoB V.2.0), 16 to determine the risk of bias.
The RoB tool contains five key domains: (1) randomisation process; (2) deviations from intended interventions; (3) missing outcome data; (4) measurement of the outcome; and (5) selective reporting. The risk of bias will be classified into three types for each domain: high, low, or some concerns. Subsequently, we will arrive at an overall risk of bias, based on judgements from the five domains. The first two authors will perform all assessments independently of each other. Any disagreements will be resolved by discussion with a third author.
Data synthesis
We will use Stata software (13.0; Stata Corporation, College Station, Texas, USA) to conduct a traditional pairwise meta-analysis. If more than five studies are included, we will use the random effects model to combine the data. Otherwise, we will use a fixed effect model, because the random effects model may be imprecise in this situation. 17 Dichotomous data will be evaluated using the risk ratio (RR) with 95% confidence interval (CI), while continuous outcomes will be expressed as standardized mean differences and 95% CI. Heterogeneity will be quantified using the I 2 statistic. If I 2 > 50%, which indicates the presence of substantial heterogeneity, 18 we will consider subgrouping the intervention by study setting (receiving formal treatment or not), gender-specific (single-gender or mixed gender), HIV testing (reported or not), methodological quality of the study, or geographical area.
When pairwise meta-analysis is completed, we will perform a network-meta analysis using WinBUGS 1.43 software. The Markov Chains Monte Carlo method will be used for Bayesian analysis. When we run the WinBUGS program, we will set it to perform 100 000 simulations, and the first 10 000 simulations will be discarded as burn-in. Convergence of the model will be assessed by trace and Gelman-Rubin-Brooks plots. 19 We will use both random-and fixed-effects models for the network analysis. Then we will select the appropriate model on the basis of the deviance information criterion (DIC); the model with the lower DIC will be preferred (a difference > 3 will be considered significant). 20 The node-splitting method will be used to statistically assess the consistency between direct and indirect evidence. 21 We will examine the assumptions of transitivity and similarity on account of clinical and methodological characteristics; notably, there is no universal statistical method to analyse these effect modifiers. 22 We plan to investigate similarity based on factors including participant characteristics, experimental design, study quality, and risk of bias, among others. Furthermore, publication bias will be assessed using comparison-adjusted funnel plots. All the figures, including forest plots for each intervention, network plots, and comparison-adjusted funnel plots, will be produced using the 'Network Graphs' package in STATA.
Confidence in cumulative evidence
We will evaluate the quality of evidence for all outcomes according to the Grading of Recommendations Assessment, Development and Evaluation (GRADE). Based on the domains of methodology quality, consistency, directness, precision effect estimates, and publication bias, we will rank the overall strength of evidence as high, moderate, low, or very low. 
ETHICS AND DISSEMINATION
This Bayesian network meta-analysis will include no confidential personal data and no data on human trials. Consequently, ethical approval is not required. The procedures used for this study will be reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) extension statement for network meta-analyses of healthcare interventions. 24 The final results will be disseminated at professional conferences and through publications in peer-reviewed journals.
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STRENGTHS AND LIMITATIONS OF THIS STUDY 31
Strengths: 32
1.This meta-analysis will make a comprehensive comparison of interventions for reducing 33 injection and sexual risk behaviours to prevent HIV in drug users. 34 Injecting drug users are known to be at higher risk of HIV infection than the general population. 
26
There have been several systematic reviews and meta-analyses of HIV interventions in people 27 who inject drugs. [5] [6] [7] [8] [9] These studies have confirmed the efficacy of interventions such as NSPs, 5, 9 28 psychosocial interventions, and IEC; 6, 7 8 however, none of the meta-analyses evaluated the effects of 29 all of these interventions, or compared the relative benefits of each; therefore, information regarding 30 whether distinct types of intervention have comparable efficacy and are equally appropriate for 31 different populations of injection drug users are lacking. 32 33
Objectives 34
In this study, we aim to compare the efficacy of all available interventions for reducing injection 35 and sexual risk behaviours to prevent HIV in drug users. A network meta-analysis can combine direct 36 and indirect evidence to provide more precise and accurate (thus both internally and externally valid) 37 effect estimates. 10 Moreover, based on effective statistical inference methods, it allows ranking of 38 investigated interventions to determine which among them is the most and least effective. 
METHODS AND ANALYSIS 41
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Eligibility criteria 4
Types of participant 5
People who inject opiates, cocaine, cannabis, and amphetamines (including 'ecstasy') will be 6 included. People who primarily misuse alcohol will be excluded. 7 8
Interventions 9
Interventions which are defined by WHO, UNODC, and UNAIDS, including: the same investigation will also be accepted.
23
Outcomes 24
Injection risk behaviour, sexual risk behaviour, or HIV seroconversion. 25 26
Study designs and publication types 27
Randomised controlled trials and peer-reviewed publications. 28
Setting 29
Setting 30
There will be no restrictions by type of clinical setting, and authors will include studies at all 31 levels of healthcare setting. 32
Language and time frame 33
We only intend to include studies which are published in English and indexed from 1980 to 34 May 2018.
36
Information sources and search strategy 37
We will search the following databases: Medline, Embase, PsycINFO, and the Cochrane Central 38
Register of Controlled Trials. The search will be performed between May and July 2018.The search 39 strategy shown below was adapted from a previous review, 13 and improved by conferring with 40 experts in a related field. The search strategies for other databases will be adjusted according to their 41 specific requirements. We will also carry out manual searches of the reference lists of other review 42 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y articles on related subjects, to retrieve additional studies not identified by our original search. The 1 following search terms will be used: 2 1. "drug users" OR "drug use" OR "drug abuse" OR "drug abuser" OR "drug abusers OR 3 "drug addict*" OR "substance abuse" OR "substance dependence" OR "drug 4 dependence" OR "drug dependency" OR "IDU" OR "IDUs" OR "injecting drug" OR 5 "intravenous drug" OR "intravenous substance" OR "injecting substance" OR exp 6 substance abuse, intravenous/ 7 2. "HIV" OR "AIDS" OR "acquired immunodeficiency syndrome" OR "Acquired 8
Immunodeficiency Syndrome Virus" OR "AIDS Virus" OR "AIDS Viruses" OR 9 "Immunologic Deficiency Syndrome, Acquired" OR "Acquired Immune Deficiency 
Study selection 20
We will import the search results into EndNote (data management software). After removing 21 duplicate articles, the first two authors will independently read the titles and abstracts to select 22 eligible articles according to the inclusion criteria. Then we will obtain the full-texts of all articles 23 which appear to meet the inclusion criteria or where there is any uncertainty. The first two authors 24 will conduct full-text reviews alone to confirm the eligibility of these articles. Cohen's Kappa (κ) 25 (calculated by R software 3.44) will be used to measure the chance-corrected agreement between the 26 two authors. Any discrepancies will be resolved by discussion with a third author and the reasons for 27 excluding articles will be recorded. 28 29
Data collection process 30
The first two authors will independently use Excel 2016 software to abstract the following 31 information from the articles collected as described above: 32 
Control characteristics 37
Any disagreements will be resolved by discussion with the third author and we will contact the 38 original authors of studies to resolve any uncertainties if necessary. 39 40
Outcome measures 41
Our primary outcome measures will be injection risk behaviours and HIV risk behaviours. HIV 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
by an antibody test will be the secondary outcome, if available. The 1 efficacy will be based on the difference in injection risk behaviours and HIV risk behaviours between 2 the intervention and comparator on the completion of intervention. HIV risk behaviours include sex 3 times (vaginal or anal), frequency of condoms used when had sex, whether engaging in sex with 4 other partners concurrently. Injection risk behaviour will be defined as having shared syringes, 5 containers, filters or water to inject drugs in the previous month and backloading/frontloading. We 6 will review all the acquired full-texts to check the relative scale used by each study, for example the 7 HIV Risk-Taking Behaviour Scale, 14, 15 to assess the above indicators. 8 9
Risk of bias in individual studies 10
We will use the Cochrane revised tool, Risk of Bias (RoB V.2.0), 16 to determine the risk of bias. 11
The RoB tool contains five key domains: (1) randomisation process; (2) deviations from intended 12 interventions; (3) missing outcome data; (4) measurement of the outcome; and (5) selective reporting. 13
The risk of bias will be classified into three types for each domain: high, low, or some concerns. 14 Subsequently, we will arrive at an overall risk of bias, based on judgements from the five domains. A 15 summary of risk of bias of all the domains will be provided for each trial. The first two authors will 16 perform all assessments independently of each other. Any disagreements will be resolved by 17 discussion with a third author.
19
Data synthesis 20
We will use Stata software (13.0; Stata Corporation, College Station, Texas, USA) to conduct a 21 traditional pairwise meta-analysis. If more than five studies are included, we will use the random 22 effects model to combine the data. Otherwise, we will use a fixed effect model, because the random 23 effects model may be imprecise in this situation. 17 Dichotomous data will be evaluated using the risk 24 ratio (RR) with 95% confidence interval (CI), while continuous outcomes will be expressed as 25 standardized mean differences and 95% CI. Heterogeneity will be quantified using the I 2 statistic. If 26 I 2 > 50%, which indicates the presence of substantial heterogeneity, 18 we will consider subgrouping 27 the intervention by study setting (receiving formal treatment or not), gender-specific (single-gender 28 or mixed gender), HIV testing (reported or not), methodological quality of the study, drug types or 29 geographical area. 30
When pairwise meta-analysis is completed, we will perform a network meta-analysis using 31 WinBUGS 1.43 software. The Markov Chains Monte Carlo method will be used for Bayesian 32 analysis. When we run the WinBUGS program, we will set it to perform 100 000 simulations, and 33 the first 10 000 simulations will be discarded as burn-in. Convergence of the model will be assessed 34 by trace and Gelman-Rubin-Brooks plots. 19 
35
We will use both random-and fixed-effects models for the network meta-analysis. Then we will 36 select the appropriate model on the basis of the deviance information criterion (DIC); the model with 37 the lower DIC will be preferred (a difference > 3 will be considered significant). 20 The node-splitting 38 method will be used to statistically assess the consistency between direct and indirect evidence. 21 
39
We will examine the assumptions of transitivity (similarity in the distribution of potential effect 40 modifiers across the different pairwise comparisons) on account of clinical and methodological 41 characteristics; notably, there is no universal statistical method to analyse these effect modifiers. We plan to investigate similarity based on factors including participant characteristics, experimental 1 design, study quality, and risk of bias, among others. 2 Furthermore, publication bias will be assessed using comparison-adjusted funnel plots. All the 3 figures, including forest plots for each intervention, network plots, and comparison-adjusted funnel 4 plots, will be produced using the 'Network Graphs' package in STATA. 5
22-23
42
We will performed sensitivity analysis to address whether the combined estimates of the 6 interventions are dominated by one or several studies, especially those with a high risk of bias. Then 7 we will exclude the trials to test the robustness of our study result. Second, we will test whether the 8 imputation of the missing values affects the result of the meta-analysis. 9 10
Confidence in cumulative evidence 11
We will evaluate the quality of evidence for all outcomes according to the Grading of 12
Recommendations Assessment, Development and Evaluation (GRADE). Based on the domains of 13 methodology quality, consistency, directness, precision effect estimates, and publication bias, we will 14 rank the overall strength of evidence as high, moderate, low, or very low. 24 
15
Patient and public involvement 16
Patients will not be involved. 17
ETHICS AND DISSEMINATION 18
This Bayesian network meta-analysis will include no confidential personal data and no data on 19 human trials. Consequently, ethical approval is not required. The procedures used for this study will 20 be reported in accordance with the Preferred Reporting Items for Systematic Reviews and 21
Meta-Analysis (PRISMA) extension statement for network meta-analyses of healthcare 22
interventions. 25 The final results will be disseminated at professional conferences and through 23 publications in peer-reviewed journals. 24 25
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Ethics and dissemination 29
The results of this study will be disseminated at professional conferences and via publications in 30 peer-reviewed journals. This study will not include any confidential personal data or data on human 31 trials; therefore, ethical approval is not required. 32 PROSPERO registration number: CRD42018086999. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 3. This protocol is written in strict accordance with the Preferred Reporting Items for 7 Systematic Reviews and Meta-Analyses Protocols (PRISMA-P). 8
4. This meta-analysis will be limited to studies which are published in English language and 9 have been peer reviewed. 10 5. Given this meta-analysis will only include randomised controlled trials (RCTs), there is a 11 possibility that the study participant population will not be representative of the overall population. 12 We only focus on persons who inject drugs and interventions defined by WHO, UNODC, and 13 UNAIDS(nor all interventions).
INTRODUCTION 15
Injecting drug users are known to be at higher risk of HIV infection than the general population. HIV is a major contributor to the disease burden attributable to drug use globally. 4 Effective 25 interventions are necessary to address HIV in injection drug users. There is a comprehensive package 26 of nine interventions, endorsed by UNAIDS, UNODC, and WHO, for the prevention, treatment, and 27 care of HIV in injecting drug users (IDUs), which includes: needle and syringe programmes (NSPs); 28 opioid substitution therapy (OST); antiretroviral therapy; and targeted information, education, and 29 communication (IEC) (among other measures). 1 
30
There have been several systematic reviews and meta-analyses of HIV interventions in injecting 31 drug users. [5] [6] [7] [8] [9] These studies have confirmed the efficacy of interventions such as NSPs, 5, 9 32 psychosocial interventions, and IEC; 6, 7 8 however, none of the meta-analyses evaluated the effects of 33 all of these interventions, or compared the relative benefits of each; therefore, information regarding 34 whether distinct types of intervention have comparable efficacy and are equally appropriate for 35 different populations of injection drug users are lacking. 36 37 Objectives 38
In this study, we aim to compare the efficacy of all available interventions for reducing injection 39 and sexual risk behaviours to prevent HIV in injection drug users.
41 METHODS AND ANALYSIS
42
A network meta-analysis can combine direct and indirect evidence to provide more precise and F o r p e e r r e v i e w o n l y 1 accurate (thus both internally and externally valid) effect estimates. 10 Moreover, based on effective 2 statistical inference methods, it allows ranking of investigated interventions to determine which among 3 them is the most and least effective. 11 4 This protocol follows the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 5 Protocols (PRISMA-P). 12 It has also been registered in the International Prospective Register of 6 Systematic Reviews (trial registration number: CRD42018086999). 7 8 Eligibility criteria for reports focused on 9 Types of participant 10
People who inject opiates, cocaine, cannabis, and amphetamines (including 'ecstasy') will be 11 included. People who primarily misuse alcohol will be excluded. We will include studies which are published in English and published from 1980 to May 2018. 37 38 Information sources and search strategy 39
We will search the following databases: Medline, Embase, PsycINFO, and the Cochrane 40 Central Register of Controlled Trials. The search will be performed between May and July 2018.The 41 search strategy shown below was adapted from a previous review, 13 and improved by conferring 42 with experts in a related field. The search strategies for other databases will be adjusted according to 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 F o r p e e r r e v i e w o n l y 1 their specific requirements. We will also carry out manual searches of the reference lists of other 2 review articles on related subjects, to retrieve additional studies not identified by our original search. 3 The following search terms will be used: 4 1. "drug users" OR "drug use" OR "drug abuse" OR "drug abuser" OR "drug abusers OR 5 "drug addict*" OR "substance abuse" OR "substance dependence" OR "drug 6 dependence" OR "drug dependency" OR "IDU" OR "IDUs" OR "injecting drug" OR 7 "intravenous drug" OR "intravenous substance" OR "injecting substance" OR exp 8 substance abuse, intravenous/ 9 2. "HIV" OR "AIDS" OR "acquired immunodeficiency syndrome" OR "Acquired 10
Immunodeficiency Syndrome Virus" OR "AIDS Virus" OR "AIDS Viruses" OR 11 "Immunologic Deficiency Syndrome, Acquired" OR "Acquired Immune Deficiency 22 We will import the search results into EndNote (data management software). After removing 23 duplicate articles, the first two authors will independently read the titles and abstracts to select 24 eligible articles according to the inclusion criteria. Then we will obtain the full-texts of all articles 25 which appear to meet the inclusion criteria or where there is any uncertainty. The first two authors 26 will conduct full-text reviews independently to confirm the eligibility of these articles. Cohen's 27 Kappa (κ) (calculated by R software 3.44) will be used to measure the chance-corrected agreement 28 between the two authors. Any discrepancies will be resolved by discussion with a third author and 29 the reasons for excluding articles at full report will be recorded. 30 31 Data collection process 32 The first two authors will independently use Excel 2016 software to abstract the following 33 information from the articles collected as described above: 34 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 F o r p e e r r e v i e w o n l y 1 characteristics; notably, there is no universal statistical method to analyse these effect modifiers. [22] [23] 2 We plan to investigate similarity based on factors including participant characteristics, experimental 3 design, study quality, and risk of bias, among others. 4
Furthermore, publication bias will be assessed using comparison-adjusted funnel plots. All the 5 figures, including forest plots for each intervention, network plots, and comparison-adjusted funnel 6 plots, will be produced using the 'Network Graphs' package in STATA. 7
We will performed sensitivity analysis to address whether the combined estimates of the 8 interventions are dominated by one or several studies, especially those with a high risk of bias. Then 9 we will exclude the trials to test the robustness of our study result. Second, we will test whether the 10 imputation of the missing values affects the result of the meta-analysis. 11 12 Confidence in cumulative evidence 13 We will evaluate the quality of evidence for all outcomes according to the Grading of 14 Recommendations Assessment, Development and Evaluation (GRADE). Based on the domains of 15 methodology quality, consistency, directness, precision effect estimates, and publication bias, we 16 will rank the overall strength of evidence as high, moderate, low, or very low. 24 
18 Patient and public involvement 19
Patients will not be involved.
21 ETHICS AND DISSEMINATION 22
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